Covid 19 Research using Clinical Trials (Home Page)
Report for D009422: Nervous System Diseases NIH
(Synonyms: Nervous Sys, Nervous Syste, Nervous System Disease, Nervous System Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug224 | COVID-19 swap test PCR Wiki | 1.00 |
| drug336 | DAS181 Wiki | 0.50 |
| drug850 | Placebo Wiki | 0.09 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012640 | Seizures NIH | 1.00 |
| D003072 | Cognition Disorders NIH | 1.00 |
| D004827 | Epilepsy NIH | 1.00 |
| D060825 | Cognitive Dysfunction NIH | 0.71 |
| D020521 | Stroke NIH | 0.50 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001268 | Mental deterioration HPO | 0.71 |
| HP:0001250 | Seizure HPO | 0.71 |
| HP:0001297 | Stroke HPO | 0.50 |
There is one clinical trial.
Clinical Trials
1 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms
The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
NCT04377425 Neurological Diseases or Conditions Stroke, Acute Seizure Disorder Diagnostic Test: COVID-19 swap test PCR MeSH:Stroke Seizures Epilepsy Cognition Disorders Cognitive Dysfunction Nervous System Diseases
HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke
Primary Outcomes
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 months
Secondary Outcomes
Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 months
Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 months
Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 months
Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 months
Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 months
Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 months
HPO Nodes
Primary Outcomes
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsSecondary Outcomes
Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 months